MIV 711

Drug Profile

MIV 711

Alternative Names: MIV-711

Latest Information Update: 27 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medivir AB
  • Class Antineoplastics; Osteoporosis therapies; Small molecules
  • Mechanism of Action Cathepsin K inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteoarthritis
  • Discontinued Bone metastases; Osteoporosis

Most Recent Events

  • 27 Feb 2018 Phase-I clinical trials in Osteoarthritis (In healthy volunteers) in USA (PO, Tablet) (NCT03443453)
  • 17 Feb 2018 Medivir completes a phase I trial in Healthy volunteers in USA (NCT03443453)
  • 19 Jan 2018 Phase-I clinical trials in Osteoarthritis (In healthy volunteers) in USA (PO, Capsule) (NCT03443453)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top